Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
144 Leser
Artikel bewerten:
(0)

Genomma Lab Internacional: Changes in Organization Structure

MEXICO CITY, Oct. 24 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company announced the following:

We are pleased to announce the appointment of Ms. Patricia Faci Villalobos as the new Vice President of Operations of Genomma Lab Internacional S.A.B de C.V., reporting to our Chief Executive Officer, Rodrigo Herrera. As Vice President of Operations, Ms. Faci will lead the Sales, Supply Chain, IT, Finance and Administration, R&D and International areas while our CEO will continue to oversee Marketing, Commercial Strategy, and Corporate Relations directly.

Ms. Faci was Chief Executive Officer of Grupo Quan for more than 4 years. Previously with the same group she acted as Chief Executive Officer of Laboratorios Kener and as Chief Financial Officer for "Helados Holanda." Before Grupo Quan, Ms. Faci held various administrative and operative positions at DESC: GIRSA (Grupo Industrial Resistol). Ms. Faci was President of CANIFARMA (Camara Nacional de la Industria Farmaceutica) (2005-2007); Board Member of CANIFARMA in 2004; Vice President of CANIFARMA in 2003 and has participated in many industry-related chambers as well as associations. Ms. Faci earned a graduate degree in Chemical Engineering from the Universidad La Salle and participated in Top Management courses at the Instituto Panamericano de Alta Direccion de Empresas.

We believe that with Ms. Faci's management expertise and leadership, Genomma Lab will be in a better position to capitalize the existing opportunities in the market.

Additionally, we are also pleased to announce the incorporation of Mr. Oscar Villalobos-Torres as the Company's new Chief Financial Officer, substituting Ms. Kristi King Etchberger.

Mr. Villalobos has worked in the past 10 years principally in Grupo IMSA where he worked in various finance and administrative positions. He also managed diverse M&A transactions and was involved in financial and strategic planning activities. Before, Mr. Villalobos lead the treasury and planning areas in Internacional de Ceramica from 1993 to 1998. Mr. Villalobos obtained an MBA from the Universidad de Chihuahua; obtained a graduate degree in Administration and Finance from University of Texas; has performed managerial courses in the Instituto Panamericano de Alta Direccion de Empresa; has studied International Business and Economic Law at George Washington University; and has a graduate degree in Finance from Instituto Tecnologico y de Estudios Superiores de Monterrey.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model, the Company has grown its revenue at a compounded annual growth rate of 64.4% from 2005 to 2007.

The Company had net sales of Ps. 1,872.9 million and EBITDA of Ps. 460.5 million in 2007. Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Web Site: http://www.genommalab.com/

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.